Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

AACR MEETING: O-Vax Ovarian Cancer Vaccine Causes Immune Response NEW ORLEANS, LA -- March 31, 1998 -- Results from immunological tests of Avax Technologies, Inc.’s experimental vaccine of haptenized autologous ovarian cancer cells, O-Vax(TM) show that the vaccine delivers a positive immune response. The results were presented by David Berd, MD, professor of medicine at Thomas Jefferson University's Kimmel Cancer Center, at the 1998 Annual Meeting of the American Association for Cancer Research in New Orleans, LA. Dr. Berd is the inventor of the company's in-licensed autologous cell vaccine technology and the chairman of Avax’s scientific advisory board. Dr. Berd's presentation reported on the results to date of the ongoing Phase I/II clinical trial for O-Vax which is being conducted at TJU. The paper discussed a treatment for Stage III ovarian cancer patients. After surgical debulking and six cycles of standard chemotherapy (taxol plus either cisplatin or carboplatin), these patients received six weekly doses of O-Vax. The patients were tested for delayed-type hypersensitivity, a measure of the activity of T lymphocytes, both before treatment and again two-and-a-half weeks after the last vaccine dose. The study showed that six of the seven vaccinated patients developed an immune response to their own ovarian cancer cells, as measured by DTH. The study also measured the patients' immune response to their own haptenized ovarian cancer cells. All developed a strong, positive immune response, as measured by DTH. Avax initiated trials for O-Vax following earlier results obtained from patients with Stage II melanoma who had been treated with M-Vax(TM), the company's initial AC Vaccine for the treatment of melanoma. As previously reported, M-Vax is believed by Avax to be the first therapeutic cancer vaccine to show a substantial increase in the survival rate for patients with Stage III melanoma. The results of the M-Vax trials to date have also shown that a positive DTH to unmodified tumour cells was predictive of overall survival of patients with Stage III melanoma. E-mail this page to a friend or colleague! To print, use this version